Pure Financial Advisors LLC Takes Position in IQVIA Holdings Inc. $IQV

Key Points

• Pure Financial Advisors LLC acquired a new stake in IQVIA Holdings Inc., purchasing 13,557 shares valued at approximately $2.14 million.
• Institutional investors now own 89.62% of IQVIA's stock, with several other firms significantly increasing their holdings during the second quarter.
• IQVIA reported a quarterly EPS of $2.81, surpassing estimates, and has set a FY 2025 guidance of $11.750-$12.050 EPS.

Pure Financial Advisors LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 13,557 shares of the medical research company's stock, valued at approximately $2,136,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BSW Wealth Partners boosted its position in IQVIA by 28.6% in the second quarter. BSW Wealth Partners now owns 1,981 shares of the medical research company's stock valued at $312,000 after buying an additional 441 shares in the last quarter. PGGM Investments raised its stake in shares of IQVIA by 115.2% in the second quarter. PGGM Investments now owns 198,698 shares of the medical research company's stock worth $31,313,000 after acquiring an additional 106,347 shares during the last quarter. Truist Financial Corp raised its stake in shares of IQVIA by 8.4% in the second quarter. Truist Financial Corp now owns 159,707 shares of the medical research company's stock worth $25,168,000 after acquiring an additional 12,424 shares during the last quarter. Broadway Wealth Solutions Inc. raised its stake in shares of IQVIA by 33.2% in the second quarter. Broadway Wealth Solutions Inc. now owns 1,944 shares of the medical research company's stock worth $306,000 after acquiring an additional 484 shares during the last quarter. Finally, Chicago Capital LLC bought a new position in shares of IQVIA in the second quarter worth about $872,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on IQV. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group boosted their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Evercore ISI boosted their price target on shares of IQVIA from $170.00 to $180.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 9th. Robert W. Baird boosted their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Finally, Jefferies Financial Group raised shares of IQVIA from a "hold" rating to a "buy" rating and boosted their price target for the stock from $195.00 to $225.00 in a research note on Tuesday, September 9th. Eighteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $230.32.

IQVIA Stock Up 0.2%

Shares of NYSE:IQV opened at $204.25 on Friday. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $237.34. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market capitalization of $34.72 billion, a PE ratio of 29.56, a PEG ratio of 2.24 and a beta of 1.32. The company has a 50 day moving average price of $187.74 and a two-hundred day moving average price of $167.57.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.